ArticleDrugs in R&D2017

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.

Hiroki Wakabayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.